Back to search

Netherlands· NL-36dab5a1d991

Omjjara 100 mg, filmomhulde tabletten

A momelotinib product containing momelotinibdihydrochloride 1-water, registered in Netherlands by GlaxoSmithKline Trading Services Limited. The same ATC class is registered in 15 of our 19 countries.

ATC L01EJ04

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedOmjjara 100 mg, filmomhulde tablettenATCL01EJ04REGISTER NO.NL-36dab5a1d991PACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Momelotinib is registered in 15 of 19 countries.

Countries holding a registration under ATC L01EJ04 (momelotinib), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 9 of them publish a price we can compare per daily dose

Momelotinib · ATC L01EJ04

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Japan
  • Netherlands
  • Norwayprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of momelotinib costs, country by country.

Normalised to the WHO defined daily dose (0.2 g), the median price runs from $0.16 in France to $309.44 in Switzerland — a ×1929 gap.

  • 2 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Momelotinib · price per daily dose (0.2 g)

USD · FX 28 Sept 2026

  • CH Switzerland$309.44
  • FR France$0.16
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
MOMELOTINIBDIHYDROCHLORIDE 1-WATER
Manufacturer
GlaxoSmithKline Trading Services Limited
Country
Netherlands (NL)
ATC code
L01EJ04
ATC class
Momelotinib
Defined daily dose
0.2 g, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/23/1782

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/55188c2a-7573-45a4-8d36-c49bf3aa8b16
GET /v1/drugs/55188c2a-7573-45a4-8d36-c49bf3aa8b16?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/omjjara-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Momelotinib",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp130773",
  "excipients": [
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "IJZEROXIDE GEEL (E 172)",
    "IJZEROXIDE ROOD  (E 172)",
    "LACTOSE 1-WATER",
    "MACROGOL 3350",
    "MAGNESIUMSTEARAAT (E 470b)",
    "NATRIUMZETMEELGLYCOLAAT",
    "POLYVINYLALCOHOL (E 1203)",
    "PROPYLGALLAAT (E 310)",
    "SILICIUMDIOXIDE (E 551)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "MOMELOTINIBDIHYDROCHLORIDE 1-WATER"
  ],
  "leaflet_url": null,
  "authorised_at": "2024/01/25",
  "procedure_number": "EMEA/H/C/005768",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/23/1782",
  "additional_monitoring": "Y"
}

See everything about momelotinib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.